Skip to main content
Fig. 2 | Advances in Rheumatology

Fig. 2

From: Drug survival and change of disease activity using a second janus kinase inhibitor in patients with difficult-to-treat rheumatoid arthritis who failed to a janus kinase inhibitor and subsequent biologics

Fig. 2

Changes in disease activity parameters between baseline and at six months from the initiation of a second JAK inhibitor. (A) TJC, (B) SJC, (C) VAS, (D) ESR, (E) CRP, (F) DAS28-ESR, and (G) DAS28-CRP. JAK, Janus kinase; TJC, Tender joint count; SJC, Swollen joint count; VAS, Visual analogue scale; ESR, Erythrocyte sedimentation rate; CRP, C-reactive protein; DAS28, Disease activity score

Back to article page

Advances in Rheumatology

ISSN: 2523-3106